Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Cites Meta-Analysis To Validate Surrogate Endpoint for Pfizer's Revatio

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory committee will be asked to support the use of a hemodynamic endpoint in pediatric trials of Pfizer's Revatio (sildenafil).

You may also be interested in...



Surrogate Endpoint For Pediatric PAH Gets Advisory Panel OK, But Validation Process Draws Concern

Pfizer can use a hemodynamic endpoint in pediatric trials of Revatio (sildenafil), but FDA's Cardiovascular and Renal Drugs Advisory Committee expresses enough ambiguity to spoil the precedent.

Surrogate Endpoint For Pediatric PAH Gets Advisory Panel OK, But Validation Process Draws Concern

Pfizer can use a hemodynamic endpoint in pediatric trials of Revatio (sildenafil), but FDA's Cardiovascular and Renal Drugs Advisory Committee expresses enough ambiguity to spoil the precedent.

Avandia Can Be Saved With New Warnings and REMS, Advisory Cmte. Says

Twenty of 33 committee members vote to keep rosiglitazone on the market, with most favoring stronger labeling and restrictions on prescribing.

Topics

UsernamePublicRestriction

Register

PS070964

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel